Show simple item record

dc.contributor.authorPagonabarraga, Javier
dc.contributor.authorArbelo, José Matías
dc.contributor.authorGrandas, Francisco
dc.contributor.authorLuquin, Maria-Rosario
dc.contributor.authorMartinez-Martin, Pablo 
dc.contributor.authorRodríguez-Oroz, Mari Cruz
dc.contributor.authorValldeoriola, Francesc
dc.contributor.authorKulisevsky, Jaime
dc.date.accessioned2020-03-23T13:53:51Z
dc.date.available2020-03-23T13:53:51Z
dc.date.issued2020-03-18
dc.identifier.citationBrain Sci. 2020 Mar 18;10(3). pii: E176.es_ES
dc.identifier.issn2076-3425es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9308
dc.description.abstractSafinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.es_ES
dc.description.sponsorshipThis study was funded by Zambon S.A.U. Medical writing services were funded by Zambon S.A.U.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectRAND/UCLA appropriateness methodes_ES
dc.subjectdyskinesiaes_ES
dc.subjectefficacyes_ES
dc.subjectfluctuationses_ES
dc.subjectsafetyes_ES
dc.subjectsafinamidees_ES
dc.titleA Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practicees_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32197462es_ES
dc.identifier.pubmedID32455904
dc.format.volume10es_ES
dc.format.number3es_ES
dc.format.page176es_ES
dc.identifier.doi10.3390/brainsci10030176es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/brainsci10030176es_ES
dc.identifier.journalBrain scienceses_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional